HQL - Tekla Life Sciences Investors

NYSE - NYSE Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue25,503.83755,099.87816,035.675
Cost of Revenue4,050.893,909.9133,185.616
Gross Profit21,452.94751,189.96512,850.059
Operating Expenses
Research Development---
Selling General and Administrative533.155677.652455.732
Non Recurring---
Total Operating Expenses---
Operating Income or Loss20,919.79250,512.31312,394.327
Income from Continuing Operations
Total Other Income/Expenses Net-39,325.272-39,325.272-33,840.281
Earnings Before Interest and Taxes20,919.792-1,711.475-1,338.725
Interest Expense---
Income Before Tax20,919.792-1,711.475-1,338.725
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-18,405.4850,512.313-21,445.954
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-18,405.4850,512.313-21,445.954
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-18,405.4850,512.313-21,445.954